These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6175341)

  • 1. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; James A; Silver LD; Kueppers F; James HL; Colman RW
    Biochemistry; 1982 Feb; 21(3):567-72. PubMed ID: 6175341
    [No Abstract]   [Full Text] [Related]  

  • 2. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
    Olson ST; Sheffer R; Francis AM
    Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.
    Scott CF; Schapira M; James HL; Cohen AB; Colman RW
    J Clin Invest; 1982 Apr; 69(4):844-52. PubMed ID: 7076850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen.
    Schapira M; Scott CF; Colman RW
    Biochemistry; 1981 May; 20(10):2738-43. PubMed ID: 6910423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of high molecular weight kininogen in modulating the inactivation of human plasma kallikrein by plasma protease inhibitors.
    Schapira M; James A; Scott CF; Kueppers F; James HL; Cohen AB; Colman RW
    Adv Exp Med Biol; 1983; 156():131-41. PubMed ID: 6190364
    [No Abstract]   [Full Text] [Related]  

  • 6. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; Colman RW
    Trans Assoc Am Physicians; 1981; 94():190-7. PubMed ID: 6979819
    [No Abstract]   [Full Text] [Related]  

  • 7. Inactivation of kallikrein in human plasma.
    van der Graaf F; Koedam JA; Bouma BN
    J Clin Invest; 1983 Jan; 71(1):149-58. PubMed ID: 6184384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of the regulation of plasma kallikrein by alpha 2M.
    Colman RW
    Ann N Y Acad Sci; 1994 Sep; 737():347-67. PubMed ID: 7524407
    [No Abstract]   [Full Text] [Related]  

  • 9. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor.
    Silverberg M; Longo J; Kaplan AP
    J Biol Chem; 1986 Nov; 261(32):14965-8. PubMed ID: 3639874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.
    Schapira M; Scott CF; Colman RW
    J Clin Invest; 1982 Feb; 69(2):462-8. PubMed ID: 6173399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on plasma inhibitors of plasma kallikrein using chromogenic peptide substrate assays.
    Gallimore MJ; Amundsen E; Larsbraaten M; Lyngaas K; Fareid E
    Thromb Res; 1979; 16(5-6):695-703. PubMed ID: 93313
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of human salivary kallikrein: reactivities to human plasma kininogens and proteinase inhibitors.
    Sakamoto W; Yoshikawa K; Uehara S; Nishikaze O
    J Biochem; 1983 Mar; 93(3):833-8. PubMed ID: 6553577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulation of human factor XIIa by plasma proteinase inhibitors.
    Pixley RA; Schapira M; Colman RW
    J Biol Chem; 1985 Feb; 260(3):1723-9. PubMed ID: 2578463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of human plasma kallikrein and its light chain with C1 inhibitor.
    van der Graaf F; Koedam JA; Griffin JH; Bouma BN
    Biochemistry; 1983 Sep; 22(20):4860-6. PubMed ID: 6556071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel procoagulant and anticoagulant pathways for high molecular weight kininogen coagulant function.
    Olson ST; Sheffer R; Shore JD
    Agents Actions Suppl; 1992; 38 ( Pt 1)():241-8. PubMed ID: 1466276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural inhibitors of the coagulation system.
    Messmore HL
    Semin Thromb Hemost; 1982 Oct; 8(4):267-75. PubMed ID: 6184781
    [No Abstract]   [Full Text] [Related]  

  • 17. Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation.
    Donaldson VH; Harrison RA
    Blood; 1982 Jul; 60(1):121-9. PubMed ID: 6211203
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha 2-macroglobulin and antithrombin-heparin cofactor: modulators of hemostatic and inflammatory reactions. Alpha 2-macroglobulin.
    Harpel PC; Rosenberg RD
    Prog Hemost Thromb; 1976; 3():145-89. PubMed ID: 59937
    [No Abstract]   [Full Text] [Related]  

  • 19. Interaction of plasma kallikrein with plasma proteinase inhibitors.
    Salvesen G; Virca GD; Travis J
    Adv Exp Med Biol; 1983; 156():121-30. PubMed ID: 6190363
    [No Abstract]   [Full Text] [Related]  

  • 20. New and rapid functional assay for C1 inhibitor in human plasma.
    Schapira M; Silver LD; Scott CF; Colman RW
    Blood; 1982 Apr; 59(4):719-24. PubMed ID: 6174161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.